Navigation Links
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

se events included fatigue, hand/foot syndrome and skin rash.

The lead investigator for this study is Joan Schiller, MD, professor and chief of the hematology/oncology division at the University of Texas Southwestern and Andrea L. Simmons distinguished chair in cancer research, Dallas, TX. (abstract #8014).

Thyroid Cancer

A Phase 2 Study of Sorafenib in Metastatic Thyroid Carcinoma

Findings from this single-arm Phase 2 study showed that treatment with Nexavar resulted in meaningful anti-tumor activity in the majority of patients with encouraging overall clinical benefit (disease stabilization and partial responses) in patients with advanced thyroid cancer. In the study, Nexavar was well-tolerated; the most common treatment-related adverse events included fatigue, rash, diarrhea, palmer-plantar erythema, musculoskeletal pain and weight loss. Patients enrolled in this study had been diagnosed with metastatic, iodine-refractory, unresectable or locally-advanced thyroid cancer.

The lead investigator for this study is Marcia S. Brose, MD, PhD, assistant professor, director of cancer genetics laboratory, University of Pennsylvania Health System, Philadelphia, PA. (abstract #6026).

Gastrointestinal Stromal Tumors

Activity of Sorafenib in Patients with Imatinib and Sunitinib-Resistant Gastrointestinal Stromal Tumors (GIST): A Phase 2 Trial of the University of Chicago Phase 2 Consortium

Findings from this single-arm Phase 2 study suggest that Nexavar is active and well tolerated in patients with Gleevec or Gleevec and Sutent resistant GIST. The most common treatment-emergent adverse events included hand-foot syndrome, hypertension, rash and diarrhea.

The lead investigator for this study is Lauren Wiebe, MD, fellow, University of Chicago, Chicago, IL. (abstract #10502).

Gastric/GEJ

A Phase 2 Study: Combination of Sorafenib with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Unres
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
2. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
3. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
10. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... Caring, is a 4-Star Sponsor of Operation Grow4Vets ... with unique products, programs and services to assist them ... Key Facts: , An ever-increasing ... a safe and effective treatment for pain, Post-traumatic Stress ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:10/17/2014)... 2014 With the recent changes in ... come across several challenges in creating and utilizing ... The Medical Affairs Consortium ... providing benchmarking and best practices across critical Medical ... service composed of three stages: 1) member-driven topic ...
Breaking Medicine Technology:Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Early Key Findings from the Medical Affairs Consortium Research 2
... 2011 NxStage Medical, Inc. (Nasdaq: NXTM ... announced that Jeffrey H. Burbank, CEO, received the Ernst ... New England Award in the Medical Devices category. The ... success in such areas as innovation, financial performance and ...
... ADDISON, Texas, June 17, 2011 ULURU Inc. (NYSE ... Stockholders was reconvened on June 16, 2011 for the purpose of ... to authorize the Board of Directors to amend the Company,s Restated ... to effect a reverse stock split of the Company,s outstanding common ...
Cached Medicine Technology:NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 2NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 3NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner 4ULURU Inc. Announces Voting Results of Reconvened Annual Meeting of Stockholders 2
(Date:10/19/2014)... BambooIndustry.com, one of the most popular suppliers of bamboo ... deckings . Moreover, the company has launched a special ... at deeply discounted rates. , As is known ... significance of online business nowadays. Thus, BambooIndustry.com pays a ... are striving to deliver both value and efficiency for ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... 20, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, GoDaddy and HostMonster are the best ... (Virtual Private Server) is the method of partitioning ... of which has the appearance and capabilities of ... why the site pays close attention to VPS ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... Stephen T. Greenberg, M.D., with offices in Woodbury, ... consecutive year as one of Long Island’s best cosmetic surgeons. ... nominated as the best provider for Botox injections. Glisten, his ... Spa and best Laser Treatment center on Long Island.* , ... vote for the contest once per day, per IP address. ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2
... aspirin to prevent heart problem have increased tremendously//. ... of Public Health (GSPH) and others conducted the study and ... African Americans and diabetics do not opt for aspirin therapy. ... and Europe measured regular use of aspirin among 2,163 African ...
... available at Northern Ireland jails have come in for ... committed suicide inside the premises of the prisons since ... to be addressed to prevent such incidences from recurring, ... ,Previous recommendations with regard to this ...
... regard to a ten-year-old plan to scale down the number ... the rich with regard to this however remains unchanged. The ... establishment of 34 networks for providing better treatment. As many ... ,Improvements have been made with regard to declining ...
... of the University of North Carolina, Chapel Hill (now at ... says that parental alcoholism is directly linked to illicit drug ... alcoholics (COA's) suffer because of their parent's abusive habits, but ... established between alcohol abuse in parents and drug abuse in ...
... And a new study says just that.,Due to deforestation ... collapse in orangutan populations// living in the fragmented forests ... Goossens, Lounès Chikhi, ,The main researcher, ... past hundred years. The massive effects were observed within ...
... disturbed bowel movements, abdominal pain, and the Irritable Bowel Syndrome ... Tibet, China and India. Prof Jianping Liu, lead review author, ... and that some of the traditional medicines did improve the ... trials were conducted on a small scale, so it is ...
Cached Medicine News:
Test for determination of rheumatoid factor....
The SYNCHRON CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 C...
The Array 360 CEAL streamlines processes with computer enhancements and optimizes productivity by offering an exclusive design for aliquot samples....
Inquire...
Medicine Products: